BioNTech (BNTX) shares plunge 17% after reporting Q4 losses, missing 2026 revenue expectations, and announcing co-founder departures by year-end.
Browsing: Stocks
Tesla (TSLA) shares climbed 1.2% after battery partner CATL exceeded Q4 forecasts with $3.3B profit. Learn why this matters for EV investors.
ExxonMobil and Chevron shares dropped in premarket trading after Trump’s Iran comments sent oil prices tumbling over 8%. CrowdStrike gained on upgrade.
Kohl’s (KSS) stock plummeted 9% after missing Q4 sales estimates and projecting flat to negative growth for fiscal 2026, marking five years of declines.
AMD stock climbed 5.33% after leading Xanadu’s $275M quantum computing funding round and achieving a 25x speedup in aerospace simulations using hybrid technology.
Gold climbed 1.7% to $5,192 and silver surged 6% after Trump indicated the Iran conflict may be ending. Discover what’s driving precious metal markets.
TD Cowen upgrades Rivian (RIVN) to Buy with $20 target before R2 SUV launch. Analysts forecast annual demand of 212K-335K units for the new model.
Citi picks Nvidia (NVDA), Broadcom (AVGO), Texas Instruments, and Monolithic Power as top chip stocks, driven by AI data center growth and strong earnings.
Webull (BULL) receives Buy rating from Compass Point with $9 price target suggesting 64% upside. Revenue surged 50% YoY to $165.2M on stronger trading activity.
HPE stock climbs after Q1 earnings beat estimates, Q2 guidance tops forecasts, and company raises FY2026 outlook while prioritizing higher-margin orders.
JPMorgan warns S&P 500 could drop 10% as Iran war escalates and oil exceeds $100/barrel. Morgan Stanley remains bullish despite geopolitical tensions.
Uranium Energy (UEC) stock jumped 4% after reporting Q2 revenue of $20.2M and selling uranium at $101/lb, 25% above spot price with zero debt on books.
Bill Ackman’s Pershing Square files for NYSE listing as PS, raising $2.8B in commitments. The offering follows Warren Buffett’s permanent-capital model.
NIO stock rises 6% after achieving its first quarterly operating profit. Q4 revenue of RMB34.65B exceeded expectations with strong Q1 2026 guidance.
Vertex Pharmaceuticals (VRTX) stock jumped 5% after povetacicept met primary endpoint in IgA nephropathy trial, reducing urine protein by 52% versus placebo.